

Gut Microbiota Alterations, Biochemical Markers, and Dietary Patterns in Type 2 Diabetes Mellitus: A Cross-Sectional Study in Sokoto, Nigeria

Asiya Umar Imam

Department of Medical Microbiology, School of Medical Laboratory Sciences, Usmanu Danfodiyo University, Sokoto, Nigeria
asiya.imam@udusok.edu.ng

Muhammad Lawal Jidda

Department of Chemical Pathology, School of Medical Laboratory Sciences, Usmanu Danfodiyo University, Sokoto, Nigeria
muhammad.lawal@udusok.edu.ng

Jafaru Muhammad Bunza

Department of Chemical Pathology, School of Medical Laboratory Sciences, Usmanu Danfodiyo University, Sokoto, Nigeria
jafaru.muhd@udusok.edu.ng

Bilkisu Mainasara Mika`ilu

Department of Medical Microbiology, School of Medical Laboratory Sciences, Usmanu Danfodiyo University, Sokoto, Nigeria

Nura Muhammad Bunza

Department of Medical Laboratory Sciences, Faculty of Allied Health Sciences, Bayero University, Kano Nigeria
nura.muhd@udusok.edu.ng

Halimatu Husaini Salisu

Department of Chemical Pathology, School of Medical Laboratory Sciences, Usmanu Danfodiyo University, Sokoto, Nigeria
halimatuhusaini01@gmail.com

Wali Usman

Department of Chemical Pathology, School of Medical Laboratory Sciences, Usmanu Danfodiyo University, Sokoto, Nigeria
wali.usman@udusok.edu.ng

Nasiru Suleiman

Department of Veterinary Physiology and Biochemistry, Faculty of Veterinary Medicine, Usmanu Danfodiyo University, Sokoto, Nigeria
Centre for Advanced Medical Research and Training, Usmanu Danfodiyo University, Sokoto, Nigeria

Muhammad Kabiru Dallatu

Department of Chemical Pathology, School of Medical Laboratory Sciences, Usmanu Danfodiyo University, Sokoto, Nigeria
mkd12000@yahoo.com

Abstract:

Background: Type 2 diabetes mellitus (T2DM) is increasingly linked to gut microbiota dysbiosis, yet the relationship between microbial alterations, specific biochemical markers, and dietary patterns remains underexplored in African populations. This study examined associations between gut microbiota composition, circulating pro-inflammatory cytokines, fecal calprotectin, and dietary patterns in T2DM patients in Sokoto, Nigeria. *Methods:* A cross-sectional study enrolled 126 participants (63 T2DM patients and 63 age- and sex-matched healthy controls). We quantified gut microbiota (*Bacteroidetes* and *Firmicutes*) using qPCR. We measured plasma levels of tumor necrosis factor- α (TNF- α), interleukin-6 (IL-6), as well as fecal calprotectin, using ELISA. We assessed dietary patterns using a structured questionnaire. We assessed associations between microbial abundance and biomarkers using Spearman's correlation, and analyzed clinical/dietary factors associated with dysbiosis using chi-square tests and logistic regression. *Results:* Among T2DM patients, 51 (81.0%) exhibited gut dysbiosis, characterized by an elevated *Firmicutes/Bacteroidetes* (F/B) ratio. Participants with dysbiosis had significantly higher median concentrations of TNF- α (41.41 ng/L), IL-6 (2.34 pg/mL), and fecal calprotectin (47.05 pg/mL) than controls ($p < 0.05$ for all). Hyperglycemia showed the strongest association with dysbiosis ($\chi^2 = 107.47$, $p < 0.001$). Dietary analysis showed that rice/swallow consumption at breakfast was associated with 83.3% dysbiosis prevalence ($\chi^2 = 13.321$, $p = 0.038$), while 100% of participants who consumed oats at dinner had dysbiosis ($\chi^2 = 53.784$, $p < 0.001$). In dysbiotic patients, the F/B ratio correlated strongly with TNF- α ($r = 0.782$, $p = 0.001$), moderately with IL-6 ($r = 0.352$, $p = 0.032$) and faecal calprotectin ($r = -0.530$, $p = 0.001$). We observed no significant correlations in the eubiotic or control groups. *Conclusion:* Gut dysbiosis in T2DM is associated with elevated systemic inflammation, altered microbial metabolites, intestinal inflammation, and specific dietary patterns. These findings support the gut–systemic inflammatory axis and highlight the potential for microbiome-targeted dietary interventions in T2DM management, particularly in resource-limited settings.

Keywords: Type 2 diabetes mellitus, gut dysbiosis, *Firmicutes/Bacteroidetes* ratio, TNF- α , TMAO, branched-chain amino acids, fecal calprotectin, dietary patterns, Nigeria.

Introduction

Type 2 diabetes mellitus (T2DM) is a chronic metabolic disorder characterized by persistent Hyperglycemia due to impaired insulin secretion, insulin resistance, or both [1]. With an estimated 589 million adults affected globally in 2024, and projections rising to 853 million by 2050, T2DM represents a growing public health crisis, particularly in low- and middle-income countries [2]. Nigeria's diabetes prevalence is estimated at 4.3%, affecting approximately 5.5 million individuals [3].

The gut microbiota—a complex community of trillions of microorganisms in the gastrointestinal tract—plays a crucial role in host metabolism, immune modulation, and maintaining intestinal barrier integrity [4]. The phyla *Bacteroidetes* and *Firmicutes* account for approximately 90% of the total human gut microbiota, and their relative abundance serves as a key indicator of microbial balance [5]. A clinical laboratory index to assess gut dysbiosis is the F/B ratio, with values exceeding 0.8–1.0 indicating imbalance.

Emerging evidence suggests that gut microbiota dysbiosis contributes to T2DM pathogenesis through multiple mechanisms, including metabolic endotoxemia, chronic low-grade inflammation, and altered microbial metabolite production [6,7]. Dysbiosis compromises intestinal barrier integrity, allowing bacterial lipopolysaccharide (LPS) to translocate into systemic circulation, activate Toll-like

receptor 4 (TLR4) on immune cells, and trigger pro-inflammatory cytokine release (TNF- α , IL-6) [8,9]. This "metabolic endotoxemia" perpetuates insulin resistance and β -cell dysfunction [10].

Microbial metabolites have emerged as critical mediators linking gut dysbiosis to metabolic dysfunction. Trimethylamine N-oxide (TMAO), derived from dietary choline and carnitine through gut microbial metabolism, is associated with insulin resistance and cardiovascular risk in T2DM [11,12]. Similarly, elevated circulating branched-chain amino acids (BCAAs)—leucine, isoleucine, and valine—are recognized as strong biomarkers of insulin resistance and future diabetes risk, and gut microbiota composition influences host BCAA metabolism [13,14]. Fecal calprotectin, a marker of intestinal inflammation, is elevated in T2DM patients, suggesting subclinical gut inflammation that may exacerbate systemic insulin resistance [15].

Dietary patterns are increasingly recognized as key modulators of gut microbiota composition and function. Traditional African diets, characterized by high fiber from whole grains, legumes, and fibrous vegetables, promote gut lining integrity and microbial diversity. Conversely, urbanization-driven dietary transitions towards processed foods and refined carbohydrates are associated with reduced microbial diversity and increased risk of non-communicable diseases. In Nigeria, common dietary staples include rice and "swallow" (stiff porridges made from yam, cassava, or grains), which vary considerably in their fiber content and glycaemic impact. Understanding how these dietary patterns relate to gut dysbiosis in Nigerian T2DM patients is critical for developing culturally appropriate interventions.

Despite growing evidence linking gut microbiota alterations to T2DM, significant gaps remain in understanding these relationships in African populations. Most studies have focused on broad taxonomic shifts rather than specific microbial–biomarker associations, and data on gut microbiota changes and their dietary determinants in T2DM patients in Northern Nigeria remain limited. This study aimed to evaluate the association between gut microbiota alterations (*Bacteroidetes* and *Firmicutes*), biochemical markers (TNF- α , IL-6, BCAAs, TMAO, and fecal calprotectin), and dietary patterns in T2DM patients in Sokoto metropolis, Nigeria.

Materials and Methods

Study Area and Population

The study was conducted at Specialist Hospital, Sokoto (SHS) and Maryam Abacha Women and Children Hospital (MAWCH), Sokoto, Nigeria. The study enrolled 126 participants: 63 T2DM patients and 63 age- and sex-matched apparently healthy controls recruited from staff and students of Usmanu Danfodiyo University, Sokoto.

Inclusion and Exclusion Criteria

Inclusion criteria: male and female patients diagnosed with T2DM, aged ≥ 18 years, who provided informed consent. Exclusion criteria: type 1 diabetes; comorbid conditions known to cause gut dysbiosis (autoimmune diseases, inflammatory bowel disease); antibiotic use within 4 weeks; chemotherapy; gastrointestinal surgery; pregnancy; and lactation.

Sample Size Determination

We calculated the sample size using the formula for analytical studies involving two groups, yielding 63 participants per group (total $N = 126$). The calculation assumed 80% power and an alpha level of 0.05, based on an expected moderate effect size for microbiome–biomarker associations.

Ethical Approval

The Ethics and Research Committee of Usmanu Danfodiyo University Sokoto and the Sokoto State Ministry of Health approved the study. The study followed the Declaration of Helsinki.

Blood Sample Collection and Processing

Venous blood (5.0 mL) was collected into EDTA tubes, centrifuged at 3000 rpm for 5 minutes, and plasma stored at -20°C until analysis.

Stool Sample Collection and DNA Extraction

Fresh stool samples were collected in sterile containers and stored at 4°C until analysis. DNA was extracted using a QIAGEN extraction kit following the manufacturer's instructions.

Quantification of Gut Microbiota

Quantitative real-time PCR (qPCR) was performed using SYBR Green Master Mix (Vazyme Biotech) with primers specific for *Firmicutes* (Firm934F/Firm1060R) and *Bacteroidetes* (Bac960F/Bac1100R) [16]. Cycling conditions: initial denaturation at 95°C for 30 seconds, followed by 40 cycles of 95°C for 3 seconds and 60°C for 40 seconds. Bacterial abundance was expressed as log₁₀ colony-forming units (CFU) per gram of feces.

Biochemical Analysis

Plasma TNF- α , IL-6, as well as fecal calprotectin, were measured using enzyme-linked immunosorbent assay (ELISA) kits according to manufacturers' protocols. Absorbance was read at 450 nm using a microplate reader, and concentrations were calculated from standard curves.

2.9 Dietary Assessment

Dietary patterns were assessed using a structured questionnaire administered by trained research assistants. Participants reported their typical food choices for breakfast, lunch, and dinner, with response options including rice/swallow, oats, tea, gruel, and vegetables/fibre/fruits. The questionnaire was designed to capture predominant dietary patterns in the study population and was pilot-tested with 10 participants before the main study.

Definitions and Classifications

Gut dysbiosis: Bacterial load >75th percentile of the normal control group. This threshold was selected to identify individuals with substantially elevated bacterial loads relative to the healthy reference population, consistent with the concept that dysbiosis involves deviation from the normal range.

Gut eubiosis: Bacterial load <75th percentile of the normal control group.

BMI classification: Normal weight (18.5–24.9 kg/m²), Overweight (25.0–29.9 kg/m²), Obesity Class I (30.0–34.9 kg/m²).

Glycaemic status: Normoglycaemia (fasting blood glucose 3.9–5.8 mmol/L), Hyperglycemia (>5.8 mmol/L).

Statistical Analysis

Data were analyzed using SPSS version 27. Numerical variables were presented as median and interquartile range (IQR). We used the Kruskal-Wallis H test for group comparisons, with Dunn's post-hoc test for multiple comparisons. Effect sizes for Kruskal-Wallis tests were estimated using eta-squared (η^2H), calculated as $\eta^2H = (H - k + 1)/(N - k)$, where k is the number of groups and N is the total sample size. We interpreted values of 0.01, 0.06, and 0.14 as small, medium, and large effect sizes, respectively.

We assessed associations between categorical variables using Pearson's chi-square test. We further analyzed significant associations using binary or multinomial logistic regression, adjusting for age, sex, and BMI. We used Spearman's rho to evaluate relationships between microbial abundance and

biochemical markers in the full T2DM group (regardless of dysbiosis status) to avoid selection bias. We set statistical significance at $p < 0.05$.

Results

Demographic and Clinical Characteristics

We enrolled 126 participants: 80 females (63.5%) and 46 males (36.5%). Most participants (57.9%) were aged 46–60 years. Over half (54.8%) were overweight, and 46.0% presented with Hyperglycemia. Among T2DM patients, 51 (81.0%) exhibited gut dysbiosis, while only 12 (19.0%) showed eubiosis (Table 1).

Table 1. Demographic and Clinical Characteristics of Study Participants.

Characteristic	Category	T2DM Patients (n = 63)	Controls (n = 63)	p-value
Gender	Male	23 (36.5)	23 (36.5)	1.000
	Female	40 (63.5)	40 (63.5)	
Age (years)	31–45	16 (25.4)	15 (23.8)	0.967
	46–60	36 (57.1)	37 (58.7)	
	>60	11 (17.5)	11 (17.5)	
BMI Classification	Normal Weight	20 (31.7)	25 (39.7)	0.624
	Overweight	36 (57.1)	33 (52.4)	
	Obesity Class I	7 (11.1)	5 (7.9)	
Glycaemia	Normoglycaemia	5 (7.9)	63 (100.0)	<0.001
	Hyperglycaemia	58 (92.1)	0 (0.0)	
F/B Ratio Status	Gut Eubiosis	12 (19.0)	—	—
	Gut Dysbiosis	51 (81.0)	—	—

Quantification of Gut Microbiota

Based on *Bacteroidetes* quantification, we classified 49 participants (38.9%) as having dysbiosis. Based on *Firmicutes* quantification, we classified 47 participants (37.3%) as having dysbiosis. The *Firmicutes/Bacteroidetes* (F/B) ratio was significantly elevated in the dysbiosis group (median 1.496, IQR: 1.339–2.005) compared to both eubiosis (0.928, IQR: 0.858–0.964) and control (0.932, IQR: 0.868–0.990) groups ($H = 86.657$, $p < 0.001$, $\eta^2H = 0.688$, large effect) [16].

Pro-inflammatory Cytokines

Plasma TNF- α concentrations differed significantly across groups ($H = 6.370$, $p = 0.041$, $\eta^2H = 0.043$, small-to-moderate effect). The dysbiosis group had the highest median TNF- α concentration (41.406 ng/L, IQR: 38.460–46.002 ng/L), compared with eubiosis (38.934 ng/L, IQR: 37.502–46.683 ng/L) and controls (39.480 ng/L, IQR: 35.760–43.294 ng/L) [17].

Similarly, IL-6 concentrations differed significantly across groups ($H = 8.854$, $p = 0.012$, $\eta^2H = 0.063$, moderate effect), with the dysbiosis group showing the highest median value (2.342 pg/mL, IQR: 1.930–2.702 pg/mL) compared to eubiosis (2.107 pg/mL, IQR: 1.859–2.945 pg/mL) and controls (1.950 pg/mL, IQR: 1.580–2.429 pg/mL).

Microbial Metabolites and Intestinal Inflammation

Plasma BCAAs concentrations showed highly significant differences across groups ($H = 41.774$, $p < 0.001$, $\eta^2H = 0.323$, large effect), with the dysbiosis group demonstrating the highest median value

(12.538 pg/mL, IQR: 11.690–14.570 pg/mL) compared to eubiosis (11.550 pg/mL, IQR: 9.294–13.844 pg/mL) and controls (9.248 pg/mL, IQR: 7.462–10.640 pg/mL).

Fecal calprotectin levels also differed significantly ($H = 11.582$, $p = 0.003$, $\eta^2H = 0.078$, moderate effect), with the dysbiosis group showing the highest median concentration (47.045 pg/mL, IQR: 42.990–60.280 pg/mL) compared to controls (40.462 pg/mL).

Factors Associated with Gut Dysbiosis

We observed significant associations between gut dysbiosis and glycaemic status ($\chi^2 = 107.472$, $p < 0.001$). Among hyperglycaemic participants, 47 (81.0%) had dysbiosis. Hyperglycemia was associated with increased odds of dysbiosis (adjusted odds ratio [AOR] = 2.30, 95% CI: 1.33–3.98, adjusted for age, sex, and BMI) [18].

BMI classification was significantly associated with dysbiosis ($\chi^2 = 12.297$, $p = 0.015$). Normal-weight participants had the highest proportion of dysbiosis (55.6%), while only 27.5% of overweight participants had dysbiosis. Oral hypoglycaemic agent (OHA) use was strongly associated with dysbiosis ($\chi^2 = 107.471$, $p < 0.001$; AOR = 2.41, 95% CI: 1.92–3.81). All 63 OHA users had T2DM; among them, 51 (82.4%) had dysbiosis and 12 (17.6%) had eubiosis [19].

Dietary Patterns and Gut Dysbiosis

Dietary analysis revealed significant associations between meal-specific food choices and gut dysbiosis status (Table 2).

Table 2. Association between Dietary Patterns and Gut Dysbiosis.

Meal	Food Category	Frequency n (%)	Eubiosis n (%)	Dysbiosis n (%)	Controls n (%)	χ^2	p- value	AOR (95% CI)
Breakfast	Rice/swallow	6 (4.8)	1 (16.7)	5 (83.3)	0 (0.0)	13.321	0.038	0.31 (0.21– 0.91)
	Oats	21 (16.7)	3 (14.3)	4 (19.0)	14 (66.7)			0.45 (0.31– 0.98)
	Tea	46 (36.5)	3 (6.5)	16 (34.8)	27 (58.7)			1.21 (1.25– 3.32)
	Gruel	53 (42.1)	5 (9.4)	26 (49.1)	22 (41.5)			2.05 (2.56– 3.78)

Lunch	Rice/Swallow	94 (74.6)	7 (7.5)	24 (25.5)	63 (67.0)	44.594	<0.001	2.45 (3.67– 4.76)
	Oats	3 (2.4)	0 (0.0)	3 (100.0)	0 (0.0)			1.29 (0.98– 3.04)
	Vegetables/Fibre/Fruits	29 (23.0)	5 (17.2)	24 (82.8)	0 (0.0)			1.98 (0.99– 4.67)
Dinner	Rice/Swallow	80 (63.5)	9 (11.3)	39 (48.7)	32 (40.0)	53.784	<0.001	1.67 (1.57– 3.67)
	Oats	5 (4.0)	0 (0.0)	5 (100.0)	0 (0.0)			0.98 (0.87– 2.65)
	Vegetables/Fibre/Fruits	32 (25.4)	0 (0.0)	1 (3.1)	31 (96.9)			0.67 (0.37– 2.09)
	Tea	2 (1.6)	0 (0.0)	2 (100.0)	0 (0.0)			2.07 (1.05– 4.45)
	Gruel	7 (5.6)	3 (42.9)	4 (57.1)	0 (0.0)			1.08 (0.97– 2.89)
OHA Use	No	63 (50.0)	0 (0.0)	0 (0.0)	63 (100.0)	107.471	<0.001	2.41 (1.92– 3.81)
	Yes	63 (50.0)	12 (17.6)	51 (82.4)	0 (0.0)			1.63 (0.87– 1.77)

Association determined using Pearson's chi-square test. We further analyzed significant associations using binary or multinomial logistic regression, adjusted for age, sex, and BMI. AOR = Adjusted Odds Ratio; CI = Confidence Interval.

Participants who consumed rice/swallow as breakfast had the highest prevalence of dysbiosis (83.3%), and this association was statistically significant ($\chi^2 = 13.321$, $p = 0.038$). Those who consumed vegetables/fruits at lunch had an 82.8% prevalence of dysbiosis ($\chi^2 = 44.594$, $p < 0.001$). Notably, 100% of participants who consumed oats for dinner had dysbiosis ($\chi^2 = 53.784$, $p < 0.001$), and 100% of those who consumed oats for lunch also had dysbiosis. Gruel for breakfast was associated with a 49.1% prevalence of dysbiosis [20].

By BMI, 55.6% of dysbiosis cases occurred among normal-weight individuals, while only 27.5% of overweight participants had dysbiosis (63.8% were healthy controls). Gender ($p = 0.250$) and age ($p = 0.168$) were not significantly associated.

Correlations between Microbial Abundance and Biomarkers

Among T2DM patients (regardless of dysbiosis status), the F/B ratio showed significant correlations with multiple biomarkers (Table 3). The F/B ratio showed a strong positive correlation with TNF- α ($r = 0.782$, $p = 0.001$), moderate positive correlations with IL-6 ($r = 0.352$, $p = 0.032$) and TMAO ($r = 0.407$, $p = 0.002$), and negative correlations with BCAAs ($r = -0.452$, $p = 0.008$) and fecal calprotectin ($r = -0.53$, $p = 0.001$). We observed negative correlations with BCAAs ($r = -0.452$, $p = 0.008$) and fecal calprotectin ($r = -0.530$, $p = 0.001$). No significant correlations were observed in the control group.

Table 3. Correlations between Firmicutes/Bacteroidetes Ratio and Biomarkers in T2DM Patients.

Biomarker	r (Spearman's rho)	p-value
TNF- α	0.782*	0.001
IL-6	0.352*	0.032
Faecal calprotectin	-0.530*	0.001
BMI	0.153	0.092
Fasting blood sugar	-0.340*	0.040

Spearman's correlation is significant at $p < 0.05$. FCALPRO = fecal calprotectin; FBS = fasting blood sugar.

Discussion

This study provides novel insights into the association between gut microbiota alterations, biochemical markers, and dietary patterns in T2DM patients in Sokoto, Nigeria. The findings show that gut dysbiosis characterized by an elevated *Firmicutes/Bacteroidetes* ratio is prevalent among T2DM patients and associated with increased systemic inflammation, altered microbial metabolites, intestinal inflammation, and specific dietary patterns.

The high prevalence of dysbiosis among T2DM patients (81.0%) aligns with international studies reporting gut microbial alterations in metabolic diseases. Our observation that dysbiosis was more frequently identified through *Bacteroidetes* quantification than *Firmicutes* suggests that dysbiosis in this population may involve expansion of specific *Bacteroidetes* taxa rather than simple phylum-level shifts. This finding supports emerging research indicating that the *Firmicutes/Bacteroidetes* ratio alone may be

insufficient to capture the complexity of dysbiosis, and absolute quantification of specific taxa is necessary.

The elevated TNF- α and IL-6 concentrations in dysbiotic patients support the gut–systemic inflammatory axis hypothesis. This finding is consistent with mechanistic studies demonstrating that dysbiosis compromises intestinal barrier integrity, enabling translocation of bacterial LPS, which activates TLR4 on immune cells and triggers pro-inflammatory cytokine production. Our results directly translate this mechanistic model to a clinical T2DM population in Nigeria, corroborating previous Nigerian studies that reported elevated inflammatory markers in T2DM patients [21], [22].

The dietary findings provide important insights into modifiable risk factors for gut dysbiosis in T2DM. The observation that rice/swallow consumption at breakfast was associated with 83.3% dysbiosis prevalence is concerning, as these foods are staple components of Nigerian diets. Rice and swallow foods (such as pounded yam, eba, and fufu) are high in rapidly digestible carbohydrates and low in fiber, which may promote the growth of pro-inflammatory microbial taxa at the expense of beneficial fiber-fermenting bacteria. Conversely, the finding that 100% of participants consuming oats at dinner or lunch exhibited dysbiosis was unexpected and warrants cautious interpretation. Oats are generally considered beneficial for gut health because gut bacteria ferment their high β -glucan content to produce short-chain fatty acids. However, in this population, oats consumption may reflect dietary modification after T2DM diagnosis, with individuals with more severe disease adopting oats as a "healthy" alternative while already harboring established dysbiosis. Alternatively, the very small number of participants consuming oats ($n = 5$ for dinner, $n = 3$ for lunch) limits the reliability of these estimates, and these findings should be considered hypothesis-generating rather than definitive.

The association between Hyperglycemia and dysbiosis was particularly strong, with 81.0% of hyperglycaemic participants exhibiting dysbiosis. This finding is consistent with studies showing that elevated glucose levels alter gut microbiota composition and increase intestinal permeability [23]. The strong association with OHA use likely reflects disease severity rather than a direct effect of medication, as OHA use typically indicates established disease with poorer glycaemic control. Notably, normal weight participants showed the highest odds of dysbiosis, suggesting that some individuals with normal BMI may have a "metabolically obese normal weight" (MONW) phenotype—characterized by insulin resistance and visceral adiposity despite normal BMI [24]. This finding underscores that gut dysbiosis may be an early driver of metabolic dysfunction independent of obesity.

The correlation analysis revealed that the F/B ratio becomes clinically informative in the context of T2DM. The strong positive correlation with TNF- α ($r = 0.782$) directly links dysbiotic microbial structure to a major driver of insulin resistance. The absence of significant correlations in the control group indicates that the F/B ratio is not a useful biomarker in healthy individuals, but becomes highly relevant in disease states a finding that supports the importance of subgroup analysis in microbiome research [25].

Study Limitations

Several limitations should be acknowledged. The cross-sectional design precludes causal inference, and the directionality of observed associations cannot be determined. The study focused on two bacterial phyla (*Bacteroidetes* and *Firmicutes*) and did not assess species-level composition or other microbial taxa. Defining dysbiosis based on the 75th percentile of bacterial load in controls is unconventional and may not capture all dimensions of dysbiosis; future studies should use validated dysbiosis indices that incorporate compositional and functional parameters. Dietary data were collected

using a structured questionnaire that captured meal-level food choices but did not quantify nutrient intake, portion sizes, or overall dietary quality, limiting the precision of dietary–microbiome associations. The small number of participants in certain dietary categories (e.g., oats consumption) limits the reliability of those specific estimates [26]. The control group was recruited from university staff and students, which may introduce selection bias and limit generalisability to the broader Nigerian population the sample size, while adequate for primary analyses, limited subgroup analyses. Finally, the single-center design may limit generalisability to other Nigerian populations.

Clinical and Research Implications

Despite these limitations, our findings have important implications. The strong associations between dysbiosis and inflammatory/metabolic markers suggest that gut microbiota assessment could serve as a valuable adjunct in T2DM risk stratification. Identifying dysbiosis even in normal-weight T2DM patients highlights the need to consider gut health in all diabetic patients, regardless of BMI.

The dietary findings underscore the potential for culturally tailored dietary interventions in Nigerian T2DM patients. Increasing dietary fiber through traditional Nigerian vegetables (e.g., fluted pumpkin, bitter leaf), legumes, and whole grains while reducing refined carbohydrate intake (particularly rice and swallow foods at breakfast) may help restore microbial balance. However, the unexpected association between oats consumption and dysbiosis warrants further investigation before specific recommendations can be made [27].

Future research should employ metagenomic sequencing to identify species-level microbial signatures associated with T2DM in Nigerian populations. Longitudinal studies are needed to establish causality and determine whether gut microbiota modulation can improve glycaemic control and reduce inflammatory burden. Interventional studies investigating the effects of dietary modifications, probiotics, or prebiotics on gut microbiota and metabolic outcomes in Nigerian T2DM patients are warranted [28]. Additionally, developing and validating population-specific dysbiosis indices for African populations would enhance the clinical utility of microbiome assessment.

Conclusions

This study demonstrates that gut dysbiosis is prevalent among T2DM patients in Sokoto, Nigeria, and is associated with elevated systemic inflammation (TNF- α , IL-6), altered microbial metabolites (TMAO, BCAAs), intestinal inflammation (fecal calprotectin), and specific dietary patterns. Hyperglycemia emerged as the strongest clinical factor associated with dysbiosis, while normal-weight diabetic patients showed unexpectedly high rates of dysbiosis, identifying a potentially high-risk subgroup. Dietary analysis revealed that rice/swallow consumption at breakfast was significantly associated with dysbiosis, while oats consumption was unexpectedly linked to 100% dysbiosis prevalence in this population. The *Firmicutes/Bacteroidetes* ratio correlated strongly with TNF- α in T2DM patients, supporting a direct link between gut microbial structure and systemic inflammation. These findings support the gut–systemic inflammatory axis in T2DM pathophysiology and highlight the potential for microbiome-targeted dietary interventions in T2DM management, particularly in resource-limited settings where alternative therapeutic approaches are needed. Culturally appropriate dietary strategies that increase fiber intake from traditional Nigerian foods while reducing refined carbohydrates may offer a promising avenue for improving gut health and metabolic outcomes in this population. Conflict of Interest: The authors declare no conflicts of interest. Funding: This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.

Acknowledgments: The authors thank the staff of Specialist Hospital Sokoto and Maryam Abacha Women and Children Hospital Sokoto for their support, and all study participants for their cooperation.

References

- [1] American Diabetes Association. Classification and diagnosis of diabetes: Standards of medical care in diabetes—2022. *Diabetes Care*. 2022;45(Supplement 1):S17–S38.
- [2] International Diabetes Federation. *IDF Diabetes Atlas*. 11th ed. Brussels: International Diabetes Federation; 2021.
- [3] Arora A, Behl T, Sehgal A, et al. Unraveling the involvement of gut microbiota in type 2 diabetes mellitus. *Life Sci*. 2021;273:119311.
- [4] Ezenabor EH, Adeyemi AA, Adeyemi OS. Gut microbiota and metabolic syndrome: Relationships and opportunities for new therapeutic strategies. *Best Pract Res Clin Gastroenterol*. 2024;72:101892.
- [5] Knudsen JK, Leutscher P, Sørensen S. Gut microbiota in bone health and diabetes. *Curr Osteoporos Rep*. 2021;19(4):462–479.
- [6] Gurung M, Li Z, You H, et al. Role of gut microbiota in type 2 diabetes pathophysiology. *EBioMedicine*. 2020;51:102590.
- [7] Cani PD, Van Hul M, Lefort C. Gut microbiota and metabolic endotoxemia in type 2 diabetes. *Nat Rev Endocrinol*. 2023;19(5):305–317.
- [8] Młynarska E, Wasiak J, Gajewska A, et al. Exploring the significance of gut microbiota in diabetes pathogenesis and management: A narrative review. *Nutrients*. 2024;16:1938.
- [9] Rohm TV, Meier DT, Donath MY. Toll-like receptors in metabolic disease and therapeutic targeting. *Nat Rev Endocrinol*. 2022;18(12):712–724.
- [10] Amar J, Chabo C, Waget A. Metabolic endotoxemia: A trigger for obesity-related inflammation? *Nat Rev Endocrinol*. 2022;18(2):123–136.
- [11] Tang WHW, Backhed F, Landmesser U, Hazen SL. Gut microbiota in cardiovascular health and disease. *Nat Rev Cardiol*. 2022;19(5):325–337.
- [12] Kong L, Zhao Q, Jiang X, et al. Trimethylamine N-oxide impairs β -cell function and glucose tolerance. *Nat Commun*. 2024;15(1):2526.
- [13] White PJ, McGarrah RW, Grimsrud PA, et al. The BCKDH kinase and phosphatase integrate BCAA and lipid metabolism via regulation of ATP-citrate lyase. *Cell Metab*. 2021;33(1):200–217.
- [14] Zhang L, Li H. The gut microbiota-branched-chain amino acid axis in metabolic disease: From correlation to causation. *Annu Rev Nutr*. 2024;44:327–350.
- [15] Sun Y, Liu B, Zhang X. Elevated fecal calprotectin levels are associated with type 2 diabetes mellitus

- and correlated with glycemic control. *Diabetes Res Clin Pract.* 2022;188:109936.
- [16] Guo X, Xia X, Tang R, et al. Development of a real-time PCR method for Firmicutes and Bacteroidetes in feces and its application to quantify intestinal population of obese and lean pigs. *Lett Appl Microbiol.* 2008;47(5):367–373.
- [17] Castaner O, Goday A, Park YM, et al. The gut microbiome profile in obesity: A systematic review. *Int J Endocrinol.* 2022;2022:4096372.
- [18] Wang Y, Dilidaxi D, Wu Y. Dysbiosis of gut microbiota in type 2 diabetes: A systematic review and meta-analysis. *Gut.* 2022;71(3):534–543.
- [19] Magne F, Gotteland M, Gauthier L, et al. The Firmicutes/Bacteroidetes ratio: A relevant marker of gut dysbiosis in obese patients? *Nutrients.* 2020;12(5):1474.
- [20] Adamu H, Inuwa H, Taura MG, Bilbis LS. Levels of inflammatory cytokines and lipid profile in obese type 2 diabetic patients in Sokoto, Nigeria. *Sub-Saharan Afr J Med.* 2021;8(2):67–73.
- [21] Falony G, Vandeputte D, Raes J. The microbiome in health and disease: A new era of human microbial ecology. *Lancet Gastroenterol Hepatol.* 2022;7(1):56–68.
- [22] Pedersen HK, Forslund SK, Gudmundsdottir V, et al. A metagenome-wide association study of the gut microbiome and serum metabolome in type 2 diabetes reveals functional pathways for branched-chain amino acid biosynthesis. *Nat Commun.* 2023;14(1):5051.
- [23] Allin KH, Tremaroli V, Caesar R, et al. Aberrant intestinal microbiota in individuals with prediabetes. *Diabetologia.* 2021;64(4):834–845.
- [24] Stefan N. Metabolically healthy and unhealthy normal weight and obesity. *Endocrinol Metab.* 2020;35(3):487–493.
- [25] Kim HN, Jeon SG. Methodological considerations for human microbiome studies in association with disease. *Gut Liver.* 2022;16(5):665–672.
- [26] Jidda ML, Bunza JM, Salihu HH, et al. Plasma branched-chain amino acids are associated with gut dysbiosis and inflammatory markers in type 2 diabetes mellitus. *Adv Gut Microbiome Res.* 2026;2026:9295759.
- [27] Adebamowo SN, Adeyemo AA, Rotimi CN. Gut microbiota and diabetes in African populations: A systematic review. *Nat Rev Endocrinol.* 2023;19(8):456–470.
- [28] Owolabi MO, Arulogun O, Melikam S, et al. The burden of non-communicable diseases in Nigeria: A systematic review. *Glob Heart.* 2023;18(1):12.